PLoS ONE (Jan 2019)

Human CAP cells represent a novel source for functional, miRNA-loaded exosome production.

  • Nikolas Zeh,
  • Helga Schneider,
  • Sven Mathias,
  • Nadja Raab,
  • Michael Kleemann,
  • Sabine Schmidt-Hertel,
  • Benjamin Weis,
  • Silke Wissing,
  • Nikola Strempel,
  • René Handrick,
  • Kerstin Otte

DOI
https://doi.org/10.1371/journal.pone.0221679
Journal volume & issue
Vol. 14, no. 8
p. e0221679

Abstract

Read online

Exosomes represent a promising delivery tool for nucleic acid-based pharmaceuticals. They are highly suitable for transporting therapeutic miRNAs to tumor cells, due to their natural membrane components. Further, exosomes are capable of effectively protecting nucleic acids against ribonucleases and enable the delivery of their content through cell membranes. However, no suitable production host for miRNA containing exosomes of non-tumorigenic origin has yet been identified. In this study we engineered an immortalised human amniocyte cell line (CAP® cells), whose exosomes were enriched and characterised. The cell line modifications not only enabled the production of GFP-labelled but also pro-apoptotic miRNA containing exosomes without negative influence on host cell growth. Furthermore, we demonstrated that pro-apoptotic miRNA containing CAP exosomes are taken up by ovarian cancer cells. Strikingly, delivery of functional exosomal miRNA led to downregulation of several reported target genes in the treated tumor cells. In summary, we revealed CAP cells of non-tumorigenic origin as a novel and efficient exosome production host with the potential to produce functional miRNA-loaded exosomes.